© 2026 Sinochem Nanjing Corporation,
All Right Reserved
New antifungal agents tend to appear in medicine only after persistent work and clear necessity emerge. Ravuconazole came along after terbinafine and voriconazole, at a time when options for hard-to-treat fungal infections seemed far too limited. Fungal pathogens, especially resistant strains of Candida and Aspergillus, kept catching clinicians unprepared and running out of choices. Japanese pharmaceutical firms, especially Eisai, noticed the rising concern in the 1990s. Deep structural research led to the triazole backbone that shaped ravuconazole’s chemical design. Developers aimed for a molecule that could withstand hepatic metabolism better and hit a tougher spectrum of fungi. Clinical trials, animal models, and piles of laboratory notes document tests across strains, dosages, and administration routes. Each step from bench to bedside reveals the fingerprints of real urgency in infectious disease circles.
Ravuconazole belongs to the azole-class antifungals, designed for oral and intravenous routes. The compound hinders fungal cytochrome P450 14α-demethylase, which interrupts ergosterol production—a key piece of fungal cell membrane integrity. The compound stands out for its activity against molds and yeasts that outwit older azoles. People facing fungal meningitis or deep-seated candidiasis often find little help with fluconazole or ketoconazole; here, ravuconazole can step in. Its improved bioavailability, prolonged half-life, and broad spectrum of coverage brought new hope to immunocompromised patients who faced hospital stays stretching into weeks.
Looking at ravuconazole as a white to light yellow solid, the powder freely dissolves in organic solvents but barely reacts with water—this solubility profile drives formulation research. Its molecular formula, C22H17F2N3O, and a molecular weight hovering around 377 g/mol reflect the balance of aromatic rings and triazole groups that define most modern antifungals. Analysts detail a melting point near 154-155°C. Every batch gets spectroscopy and chromatography to confirm purity and distinguish it from close analogues—crucial for consistency in a drug that targets life-threatening infections.
Labels for pharmaceutical compounds usually follow strict local regulatory guidance, listing chemical identification, concentration, batch number, storage instructions, manufacturer details, and required warnings. Purity not less than 98% by HPLC signals quality for clinical and research use. Ravuconazole must be shielded from light, kept in tightly closed containers, and stored below 25°C. Each shipment gets a certificate of analysis and clear hazard labeling under globally harmonized systems. As regulation keeps shifting, any product not up to spec goes straight back—no corners cut when patient safety rides on accuracy.
Synthetically, ravuconazole requires a multi-step reaction that forms the triazole ring and attaches key side chains. This synthesis almost always starts with haloaromatic precursors and uses reactions like nucleophilic substitution, triazole ring closure, and fluorination. Researchers navigate purification by column chromatography and crystallization to strip away byproducts. Each step demands close attention—minor impurities, especially on the triazole nitrogen or fluoro groups, can change pharmacologic behavior. Chemists in development labs still refine yields and look to cut down on solvent waste, reflecting a growing responsibility in green chemistry.
Ravuconazole’s chemical structure allows selective modifications. Medicinal chemists study how swapping out various side groups or adding substituents could stretch the antifungal spectrum. For example, converting the terminal side-chain changes the lipophilicity and alters oral absorption. Derivatives have been made to lower toxicity, dodge resistance, or overcome biofilm penetration hurdles. None so far has completely replaced the parent molecule, in part because its original balance of potency and safety still holds up in the clinic. Structure-activity relationship papers keep arriving as the field looks for the next big leap.
In scientific and commercial settings, ravuconazole often shows up under names like BMS-207147 or E-1224. Those tracking its progress in various clinical studies will spot code names linked to sponsor organizations and trial numbers. Some early papers mention "ravuconazol" or "ravuconazole hydrochloride" when discussing forms adapted for better solubility in blood plasma. As standardization improved, regulatory filings landed on “ravuconazole,” ending years of scattered references.
Dealing with any potent antifungal molecule means strict lab discipline. Researchers and factory staff both handle ravuconazole in ventilated hoods with gloves and protective gear to limit skin or inhalation exposure. Technical sheets spell out troubleshooting for spills and eye contact, and workers track potential long-term effects through health monitoring programs. Storage needs segregation from strong oxidizing agents and a controlled environment to minimize degradation. Disposal must follow hazardous pharmaceutical protocols to avoid environmental contamination—facilities contract with licensed waste handlers to keep everything aboveboard.
Doctors dealing with persistent fungal threats—especially in cancer wards, bone marrow transplant units, or advanced HIV clinics—often rely on next-generation azoles like ravuconazole. It finds its place as an alternative for invasive candidiasis, chronic aspergillosis, or rare infections by Scedosporium and Fusarium species. In tropical regions, agents like ravuconazole help address neglected fungal diseases, where older treatments offer little help. Antimicrobial stewardship programs keep a close eye to avoid resistance from overuse, securing this option for future patients.
Development in antifungal medicine often lags behind top corporate priorities, but public health pressure has pushed ravuconazole into continuing research. Animal studies have mapped liver metabolism and potential drug-drug interactions. Teams in Japan, Europe, and Latin America collect clinical outcomes from experimental regimens. Public databases log hundreds of papers on resistance, combination therapy, and even nanoparticle formulations that may soon improve oral delivery. Some major journal articles call out the need to finish halted Phase III trials so doctors can finally get hard data on this compound’s limits and benefits in diverse clinical settings.
All azoles interact with liver enzymes—especially CYP3A4—so toxicity risk centers on hepatotoxicity and rare allergic skin reactions. Early tests in rodents noted dose-related transaminase elevations, which led to careful adjustments in dosing for humans. Drug interactions with immunosuppressants, antiretrovirals, and some antibiotics need close review before starting therapy. The most recent reviews point to manageable side effects when proper precautions are taken, but new cases keep surfacing as physicians diagnose more non-standard fungal infections. Regulatory bodies in each country keep independent adverse event reporting and recommend ongoing surveillance.
The pipeline for antifungal agents often moves slowly, crowding new candidates out before they see routine clinical use. Ravuconazole’s successful application in international studies against tough invasive infections, along with oral and intravenous dosing flexibility, could keep it relevant in a growing market. Its chemical backbone gives scientists a launching pad for the next generation of modified azoles—some that may soon attack non-fungal targets or cross the blood-brain barrier with fewer side effects. Research teams are now chasing formulations to improve stability, less frequent dosing, and cost savings for resource-limited settings. Medical innovation tends to favor drugs that last; ravuconazole’s story keeps branching out as resistant fungi raise new challenges and clinical teams look for one more shot at better outcomes.
Ravuconazole stands out for people facing fungal infections that don’t go away with standard drugs. Most folks never think about fungi unless they find mold in the shower. Still, inside hospitals, fungal pathogens cause problems no bleach can fix. COVID pulled the curtain back on how dangerous fungal infections can get when a patient’s immune system struggles to keep pace.
Doctors have spent decades using azole-class antifungals against a laundry list of infections: yeast, molds, everything in between. Fluconazole and itraconazole worked for a lot of cases until resistance started popping up. When standard treatment stops working, the stakes grow higher for vulnerable patients. Old options can only do so much, and the pharmaceutical world doesn’t churn out new antifungal drugs the way it does for viruses or bacteria.
Ravuconazole entered the scene as a broad-spectrum triazole antifungal with a mechanism similar to the older options: it blocks the construction process of fungal cell membranes. This disrupts ergosterol, a molecule fungi need to function. That forces the bad actors to fold before they can get out of hand. Unlike some established triazoles, Ravuconazole packs a punch against certain hard-to-treat Candida and Aspergillus species—including those showing resistance to earlier azoles.
Fungal infections like histoplasmosis, invasive candidiasis, and aspergillosis can wreck lives without warning, especially in people fighting cancer, HIV, or taking immune suppressants. Ravuconazole gives infectious disease doctors a new direction—one less likely to run into the brick wall of drug resistance right away.
Drugs like Ravuconazole never travel a smooth road from lab to pharmacy. Safety always tops the list of concerns before a new compound gets greenlit. Triazoles, by nature, can affect more than just fungi, sometimes leading to liver issues, headaches, or gut troubles for folks taking them. Careful dosing and close monitoring help manage these risks, but sometimes they limit how widely a drug can be prescribed.
In my work volunteering in hospitals and clinics, I see firsthand the pain families feel when a loved one’s infection keeps coming back. The frustration melted away the day a trial gave a patient access to a drug like Ravuconazole—and the infection stopped spreading. Personal experience makes it clear why options matter.
Cost remains a sticking point. Pharmaceutical companies invest big money in research, and patients sometimes pick up the tab. If a patient lives in a lower-income country, access to antifungal therapies is still spotty. International organizations push for affordable pricing, but changing the system takes political will.
Solutions lie in better stewardship of the drugs we have and continued support for antifungal research. Hospitals must avoid overuse so resistance grows slower. Policy makers can invest in programs expanding access, encouraging companies to study these life-saving drugs in diverse communities where resistant infections run wild. Only a few new antifungals exist after all these years—Ravuconazole reminds us the work never ends.
Ravuconazole goes after fungal infections that often slip past our body’s frontline defenses. Many of the tough cases I’ve seen, especially with weakened immunities, involve molds or yeasts that have found ways to thrive despite older medications. Invasive aspergillosis, for example, doesn't just disrupt comfort—it can threaten lives. I know people who spent weeks in hospital due to infections that just wouldn’t go away. When doctors look at treatment charts today, many have their fingers crossed for something that can really get to the root of these fungi.
Fungi can't live without a sturdy outer layer. This armor comes from a chemical compound called ergosterol, unique to fungi. Ravuconazole goes after the enzymes that fungi use to build ergosterol, specifically the enzyme called lanosterol 14-alpha-demethylase. Block this enzyme and the fungus starts to lose its grip—its outer shell weakens, holes form, and the cell leaks until it collapses.
I remember a local pharmacist telling me how tough fungal infections can be to clear. Many medicines can temporarily slow the invader's spread, but without popping the actual shield, the fungus just waits it out, ready to flare up again. The clever bit about Ravuconazole is its selectivity—it targets the fungal equipment and leaves our human cells alone. That’s a relief for patients, avoiding the heavy toll that comes with more toxic drugs.
Fungal resistance keeps growing. People travel more, climate changes, and the use of medical devices give fungi more opportunities than they had in the past. In hospital wards, we see folks with underlying illnesses like cancer or diabetes. They’re taking drugs that suppress their immune system, making them easy targets for infection. Drugs like Ravuconazole matter because they step in where common medicines, such as fluconazole, start failing.
Studies out of Japan and Europe show that Ravuconazole holds its ground even when older drugs falter. Not only does it work against a broad spectrum of fungi, it sticks around in the blood long enough to keep working—meaning fewer pills, better compliance from patients, and reduced risk of relapse.
Safety and access remain big talking points. Every medicine has side effects, some visible, some hiding until enough people use it. I’ve seen folks get discouraged by high drug costs or patchy availability, leading them to skip doses or go without. Policymakers and healthcare teams need real-world data to understand if lab successes translate to daily living. Public health efforts should focus not just on newer drugs, but prevention—good hygiene, careful monitoring of vulnerable patients, and honest conversations about the risks of self-medicating or ignoring symptoms.
Ravuconazole’s journey isn’t done. It brings promise, especially for patients who face fungal infections that often don’t get enough attention. With proper stewardship, ongoing surveillance, and fairer access to care, the hope is that this medicine continues to work—not just in hospital trials, but in the lives of people coping with serious health challenges every day.
Ravuconazole is an antifungal medicine that fights infections most people never hear about until their doctor says the word “fungus.” It targets tough infections inside the body, mainly in people who have weakened immunity or have gone through organ transplants. I’ve seen more than a few news reports and medical bulletins praise its potency against rare but stubborn fungi, especially where other antifungals fail.
No medicine, especially one as strong as ravuconazole, is gentle on every part of the body. Those who take it usually have to stay alert for possible side effects. According to the most recent scientific studies and clinical trials, some side effects pop up more often than others. People may experience nausea, headaches, dizziness, or stomach pain. Doctors will often ask about fatigue, changes in taste, or rash. I’ve heard patients say their appetite dropped, or that they just started feeling off—sometimes it’s little things like that which are easiest to dismiss but actually matter.
Serious liver problems rank high up on the list. Blood tests can catch these issues early—elevated enzymes or jaundice force doctors to rethink a patient’s prescription. The liver works hard to process medications, and ravuconazole isn’t easy on it. Regular checkups and blood draws give early warning signs. European regulators and the FDA keep reminding healthcare professionals to weigh the risks, especially in people with a history of liver troubles.
One of the hurdles with ravuconazole: it gets tangled up with lots of other medicines. It shares some chemistry with statins, blood thinners, and certain immunosuppressants. Mixing the wrong meds can lead to confusion, bruising, or other problems that can land you back in the hospital. I’ve sat with people as their doctors walk them through huge lists of what’s safe to take and what needs to go, and it’s never quick or easy.
Folks already dealing with kidney or liver issues need to take extra care. Athletes, seniors, and those who must balance chronic conditions like diabetes or heart disease often find themselves in a complicated spot. For anyone on long-term therapy, remembering what the body puts up with—fatigue, skin dryness, or persistent stomach discomfort—turns into a daily balancing act.
Healthcare workers and pharmacists regularly remind patients to communicate every odd symptom. Too many people tough out mild side effects only to find themselves in worse trouble down the road. A practical approach means checking in, catching lab work on time, and being honest about what’s going wrong.
New research into antifungals keeps moving forward. Some reports show promise on developing variations that spare the liver or interact less with other meds. Until then, patients and doctors have to stay sharp, read the latest reports, and stay focused on weighing the benefits against the risks. Open conversations, regular monitoring, and sticking to tried-and-true advice seem to make treatment safer and more tolerable for most folks facing difficult fungal infections.
Ravuconazole once looked like the next big thing in fighting fungal infections. Plenty of scientists saw potential because nasty bugs like Aspergillus and Candida keep getting tougher due to overuse of current drugs. Some of those older drugs, like fluconazole and itraconazole, just don’t cut it when rare fungi show up or patients have weakened immune systems. Ravuconazole, a triazole antifungal, started grabbing attention in research labs more than twenty years ago because it worked well in the test tube and in animals.
Despite promising results on paper and in animal models, ravuconazole hasn’t made it from the lab to the pharmacy shelf in many countries. Ask around hospitals or pharmacies in the US or Europe—few have even heard of it, let alone stocked it. Japan comes closest: a drug called "Ravuconazole hydrochloride hydrate" has been approved for some fungal infections there, but it never reached large-scale use even at home, and nowhere else has it been picked up for standard treatment.
Ravuconazole still shows up in research papers, mostly discussing its chemical cousins, like fosravuconazole. Japan’s clinical trials moved that related molecule a step closer, especially for certain difficult fungal diseases. Yet even fosravuconazole isn’t sitting on western pharmacy counters.
Drug development rides a tough path, especially for antifungals. Ravuconazole worked in the lab, but human trials have to sort out dosing, possible liver damage, and how it interacts with other medicines. Companies also weigh dollars and cents—bringing a new antifungal drug to market costs hundreds of millions, and some don’t think the returns will add up, especially if the drug helps a small number of patients.
Big pharmaceutical firms often invest more in drugs for common diseases, like diabetes or hypertension; these bring repeat business. Rare fungal infections rarely draw headlines, even during outbreaks, so they get lost in the shuffle. Health policy experts point out that the market for antifungals feels too small for some investors, even though, for patients and doctors, the need looms large.
Lack of commercial availability for something like ravuconazole isn’t a story about just one drug; it tells a bigger story about medicine as a whole. Many potentially life-saving drugs reach the “phase II” or “phase III” clinical trial stage before running out of funds, getting blocked by regulatory issues, or losing out to older, cheaper drugs whose patents have expired. Infections from uncommon fungi rarely spark global urgency, so public sector groups and charities sometimes try to pick up the slack. Still, results come slowly, and many promising treatments get stuck in a paperwork jungle for years.
Doctors and patients living with tough fungal infections want more options. Expanding public funding to support late-stage clinical trials of drugs like ravuconazole would help. Real progress also depends on regulatory agencies fast-tracking treatments for diseases with few options. Sometimes, compassionate-use programs can help bring unapproved drugs to the sickest patients, but these programs only reach a handful of people.
Listening to stories from people living with recurring fungal infections, or from infectious disease doctors with limited tools, reminds us: without stronger partnerships between science, industry, and government, the best innovations risk gathering dust. For now, ravuconazole serves as a cautionary tale about the gap between discovery and real-world use.
Fungal infections kill hundreds of thousands every year, especially among those with weak immune systems. While there are plenty of antifungal drugs available, some older ones hit the kidneys or the liver pretty hard. Ravuconazole, a newer triazole antifungal, brings hope for infections that won’t budge with more common drugs. Knowing the best way to give this drug makes the difference between a cure and a relapse.
Ravuconazole doesn’t break down easily in the stomach. Everyone from infectious disease experts to pharmacists watches for how the body absorbs it. Most clinical studies suggest taking Ravuconazole by mouth, in tablet form. Dosing usually ranges from 100mg to 400mg, once a day. In my work with transplant patients, I’ve seen how higher doses may be recommended for more stubborn infections, but this only happens under hospital supervision.
Food doesn’t appear to interfere with absorption, and in fact, a light meal can ease stomach issues. Unlike some azoles, Ravuconazole runs a low risk of causing stomach upset or taste changes, which means patients tend to stick with the prescribed plan better. Staying consistent and finishing the full course stays just as important as with antibiotics.
Oral dosing works for most mild and moderate fungal infections. Some patients can’t take medication by mouth—think about those with feeding tubes or who can’t swallow because of severe mouth sores. In these rare cases, Ravuconazole can go through an IV line. Hospitals use IV Ravuconazole for people who need rapid action or those already too weak to risk pills. I’ve seen cases where a switch from IV to oral form keeps things rolling once someone recovers a bit.
Like other triazoles, Ravuconazole interacts with common drugs: warfarin, tacrolimus, antiepileptics, and some antibiotics just to name a few. Ignoring these combinations has led to headaches in the clinic. A good pharmacist cross-checks a patient’s medication list before starting treatment. Liver enzymes need a watchful eye too, especially early in treatment. Bloodwork once a week at the start catches trouble before it gets out of hand. Ravuconazole doesn’t usually hammer kidneys, which helps in patients with chronic kidney trouble.
Ravuconazole isn’t approved everywhere. Some regions still stick with old-school drugs or alternate azoles. Steep price tags and patchy supply slow down adoption. Doctors sometimes face hard choices—stick to less effective therapies, or reach for a drug that stretches a hospital’s budget. Partnerships between industry, governments, and hospitals could help slash those barriers and increase availability. More studies tracking outcomes in both oral and IV forms will make it easier to set international guidelines.
No two patients battle infections the same way. I’ve found that sticking closely to dosing schedules, keeping things simple, and being open about side effects wins trust. Doctors, nurses, and pharmacists learn the most by following patients through their whole journey, not just at the bedside but in phone calls and outpatient visits. People on the ground—patients, family, and caregivers—deserve support and updated information about new drugs like Ravuconazole as they become more common.
| Names | |
| Preferred IUPAC name | (2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-ol |
| Other names |
BMS-207147 ER-30346 |
| Pronunciation | /ˌrævjuːˈkəʊnəˌzɒl/ |
| Identifiers | |
| CAS Number | “182760-06-1” |
| 3D model (JSmol) | MSPTWYVXNHYFGB-UHFFFAOYSA-N |
| Beilstein Reference | 2221564 |
| ChEBI | CHEBI:88232 |
| ChEMBL | CHEMBL125474 |
| ChemSpider | 2274296 |
| DrugBank | DB06227 |
| ECHA InfoCard | 100000021090 |
| EC Number | 4.99.0.8 |
| Gmelin Reference | 1270806 |
| KEGG | D09680 |
| MeSH | D000070612 |
| PubChem CID | 213045 |
| RTECS number | UD2051610M |
| UNII | RK8Q39VR18 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C22H17F2N3O |
| Molar mass | 532.489 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.3±0.1 g/cm3 |
| Solubility in water | Insoluble in water |
| log P | 3.67 |
| Vapor pressure | 2.75E-19 mmHg |
| Acidity (pKa) | 13.94 |
| Basicity (pKb) | 2.97 |
| Magnetic susceptibility (χ) | -70.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.613 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.9951 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 344.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -23.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5615 kJ/mol |
| Pharmacology | |
| ATC code | J02AC10 |
| Hazards | |
| Main hazards | Suspected of damaging fertility or the unborn child. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P264, P270, P280, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-2-0-🌐 |
| Flash point | > Flash point: 344.1 °C |
| Explosive limits | Explosive limits: Non-explosive |
| Lethal dose or concentration | LD50 (mouse, oral): >1000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Ravuconazole: "2000 mg/kg (rat, oral) |
| NIOSH | Not listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 100 mg |
| Related compounds | |
| Related compounds |
Fluconazole Itraconazole Voriconazole Isavuconazole Posaconazole Efinaconazole Albaconazole Ketoconazole Terconazole |
